The rise and fall of endothelin receptor antagonists in congestive heart failure

European Respiratory Journal

Volumn 37, Issue 3, 2011, Pages 484-485

  Handoko, M L ^a   De Man, F S ^a,b   Vonk Noordegraaf, A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN;

CONGESTIVE HEART FAILURE; DISEASE SEVERITY; DRUG EFFICACY; EDITORIAL; HEART FUNCTION; LUNG FUNCTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SECONDARY PULMONARY HYPERTENSION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CARDIOLOGY; DISEASE MODELS, ANIMAL; HEART; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; MYOCARDIUM; PROGNOSIS; RECEPTORS, ENDOTHELIN; SULFONAMIDES;

EID: 79953718746     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00145910     Document Type: Editorial

References (15)

1. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415. (Pubitemid 18090241)
2. Nambi P, Clozel M, Feuerstein G. Endothelin and heart failure. Heart Fail Rev 2001; 6: 335-340. (Pubitemid 32725192)
3. Cody RJ, Haas GJ, Binkley PF, et al. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992; 85: 504-509.
4. Pacher R, Bergler-Klein J, Globits S, et al. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension. Am J Cardiol 1993; 71: 1293-1299. (Pubitemid 23156683)
5. Omland T, Lie RT, Aakvaag A, et al. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89: 1573-1579. (Pubitemid 24114233)
6. Wei CM, Lerman A, Rodeheffer RJ, et al. Endothelin in human congestive heart failure. Circulation 1994; 89: 1580-1586. (Pubitemid 24114234)
7. Fraccarollo D, Hu K, Galuppo P, et al. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling. Circulation 1997; 96: 3963-3973.
8. Mulder P, Richard V, Derumeaux G, et al. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 1997; 96: 1976-1982. (Pubitemid 27400761)
9. Sutsch G, Kiowski W, Yan XW, et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998; 98: 2262-2268. (Pubitemid 28533844)
10. Packer M. Multicentre, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure - results of the REACH-1 trial (abstract). Circulation 1998; 98: 1-3.
11. Mylona P, Cleland JG. Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net editorial team. Eur J Heart Fail 1999; 1: 197-200. (Pubitemid 30186712)
12. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 2002; 85: 195-197.
13. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903. (Pubitemid 34984638)
14. Kaluski E, Cotter G, Leitman M, et al. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension - a multi-center randomized study. Cardiology 2008; 109: 273-280. (Pubitemid 351328923)
15. Jiang BH, Tardif J-C, Shi Y, et al. Bosentan does not improve pulmonary hypertension and lung remodelling in heart failure. Eur Respir J 2011; 37: 578-586.